<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002456</url>
  </required_header>
  <id_info>
    <org_study_id>RRP 09-136</org_study_id>
    <secondary_id>VMS #120</secondary_id>
    <nct_id>NCT01002456</nct_id>
  </id_info>
  <brief_title>Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison</brief_title>
  <official_title>Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the proposed pilot study is to begin evaluation of two methods for
      promoting adherence to guidelines for beta-blocker therapy in heart failure. The design
      includes site level baseline measurement, feedback, remeasurement after six months, and
      randomized (by site) comparison samples. The setting is VA sites, with intervention directed
      at the pharmacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current evidence-based guidelines in VA recommend one of three beta-blockers (carvedilol,
      metoprolol succinate, or bisoprolol) that have been shown to reduce mortality in heart
      failure patients with systolic dysfunction, with recommended target doses. However, Pharmacy
      Benefits Management (PBM) data indicate that prescribing for beta-blockers in heart failure
      patients that is not in accordance with guidelines is substantial, both in terms of the agent
      selected and the dose. Sites will be recruited and randomized to two different intensities of
      intervention to promote adherence to guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Adherence to Guideline Prescription</measure>
    <time_frame>6 months</time_frame>
    <description>full adherence to guideline medication and dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Toward Adherence to Guideline Prescription</measure>
    <time_frame>6 months</time_frame>
    <description>either change to a guideline agent or dose increase of a guideline agent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Level 1: site-specific information</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>provide site-specific information on nonadherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2: site-, patient-specific info</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>provide site- and patient-specific information on nonadherence</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Level 1: (provide site-specifi information)</intervention_name>
    <description>provide site-specific information on non-adherence to guideline</description>
    <arm_group_label>Level 1: site-specific information</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Level 2 (Provide site- and patient-specific information)</intervention_name>
    <description>provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions</description>
    <arm_group_label>Level 2: site-, patient-specific info</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VA sites

          -  Males and females

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeline McCarren, PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward Hines Jr. VA Hospital, Hines, IL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2014</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Guideline Adherence</keyword>
  <keyword>Drug Prescriptions</keyword>
  <keyword>target dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>provide site-specific information
Level 1 (Provide site-specific information): provide site-specific information on non-adherence to guideline</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>provide site- and patient-specific information
Level 2 (Provide site- and patient-specific information): provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Level 1</title>
          <description>site-specific information provided</description>
        </group>
        <group group_id="B2">
          <title>Level 2</title>
          <description>site- and patient-specific information provided</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="11.5"/>
                    <measurement group_id="B2" value="71" spread="11.0"/>
                    <measurement group_id="B3" value="71" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Adherence to Guideline Prescription</title>
        <description>full adherence to guideline medication and dose</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Level 1</title>
            <description>provide site-specific information</description>
          </group>
          <group group_id="O2">
            <title>Level 2</title>
            <description>provide site- and patient-specific information</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adherence to Guideline Prescription</title>
          <description>full adherence to guideline medication and dose</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Proportional odds ratio to measure the trend of change in concordance with guideline recommendations, with Arm 1 as the comparator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progress Toward Adherence to Guideline Prescription</title>
        <description>either change to a guideline agent or dose increase of a guideline agent</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Level 1: Provide Site-specific Information</title>
            <description>Level 1: provide site-specific information on nonadherence</description>
          </group>
          <group group_id="O2">
            <title>Level 2:Provide Site- and Patient-specific Information</title>
            <description>Level 2:provide site- and patient-specific information on nonadherence</description>
          </group>
        </group_list>
        <measure>
          <title>Progress Toward Adherence to Guideline Prescription</title>
          <description>either change to a guideline agent or dose increase of a guideline agent</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Level 1: Provide Site-specific Information</title>
          <description>Level 1: provide site-specific information on non-adherence</description>
        </group>
        <group group_id="E2">
          <title>Level 2: Provide Site- and Patient-specific Information</title>
          <description>Level 2: provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Madeline McCarren</name_or_title>
      <organization>Dept. of Veterans Affairs</organization>
      <phone>708 786 7987</phone>
      <email>madeline.mccarren@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

